Literature DB >> 33396303

Adaptation to Endoplasmic Reticulum Stress Enhances Resistance of Oral Cancer Cells to Cisplatin by Up-Regulating Polymerase η and Increasing DNA Repair Efficiency.

Cho-Yi Chen1, Masaoki Kawasumi2, Tien-Yun Lan3, Chi-Lam Poon1, Yi-Sian Lin1, Pin-Jou Wu1, Yao-Chung Chen1, Bing-Hong Chen3, Cheng-Hsien Wu4,5, Jeng-Fan Lo6, Rueyhung Roc Weng7, Yi-Chen Sun8, Kai-Feng Hung3,4.   

Abstract

Endoplasmic reticulum (ER) stress response is an adaptive program to cope with cellular stress that disturbs the function and homeostasis of ER, which commonly occurs during cancer progression to late stage. Late-stage cancers, mostly requiring chemotherapy, often develop treatment resistance. Chemoresistance has been linked to ER stress response; however, most of the evidence has come from studies that correlate the expression of stress markers with poor prognosis or demonstrate proapoptosis by the knockdown of stress-responsive genes. Since ER stress in cancers usually persists and is essentially not induced by genetic manipulations, we used low doses of ER stress inducers at levels that allowed cell adaptation to occur in order to investigate the effect of stress response on chemoresistance. We found that prolonged tolerable ER stress promotes mesenchymal-epithelial transition, slows cell-cycle progression, and delays the S-phase exit. Consequently, cisplatin-induced apoptosis was significantly decreased in stress-adapted cells, implying their acquisition of cisplatin resistance. Molecularly, we found that proliferating cell nuclear antigen (PCNA) ubiquitination and the expression of polymerase η, the main polymerase responsible for translesion synthesis across cisplatin-DNA damage, were up-regulated in ER stress-adaptive cells, and their enhanced cisplatin resistance was abrogated by the knockout of polymerase η. We also found that a fraction of p53 in stress-adapted cells was translocated to the nucleus, and that these cells exhibited a significant decline in the level of cisplatin-DNA damage. Consistently, we showed that the nuclear p53 coincided with strong positivity of glucose-related protein 78 (GRP78) on immunostaining of clinical biopsies, and the cisplatin-based chemotherapy was less effective for patients with high levels of ER stress. Taken together, this study uncovers that adaptation to ER stress enhances DNA repair and damage tolerance, with which stressed cells gain resistance to chemotherapeutics.

Entities:  

Keywords:  DNA repair; chemoresistance; cisplatin; damage tolerance; endoplasmic reticulum (ER) stress response; polymerase η

Year:  2020        PMID: 33396303     DOI: 10.3390/ijms22010355

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  4 in total

1.  Genome-wide association study for grain mineral content in a Brazilian common bean diversity panel.

Authors:  Jessica Delfini; Vânia Moda-Cirino; José Dos Santos Neto; Douglas Mariani Zeffa; Alison Fernando Nogueira; Luriam Aparecida Brandão Ribeiro; Paulo Maurício Ruas; Paul Gepts; Leandro Simões Azeredo Gonçalves
Journal:  Theor Appl Genet       Date:  2021-05-24       Impact factor: 5.699

2.  Interplay Between Thiamine and p53/p21 Axes Affects Antiproliferative Action of Cisplatin in Lung Adenocarcinoma Cells by Changing Metabolism of 2-Oxoglutarate/Glutamate.

Authors:  Vasily A Aleshin; Xiaoshan Zhou; Shuba Krishnan; Anna Karlsson; Victoria I Bunik
Journal:  Front Genet       Date:  2021-04-01       Impact factor: 4.599

3.  DNA polymerase η promotes nonhomologous end joining upon etoposide exposure dependent on the scaffolding protein Kap1.

Authors:  Xiaolu Ma; Chen Wang; Bo Zhou; Zina Cheng; Zhiyong Mao; Tie-Shan Tang; Caixia Guo
Journal:  J Biol Chem       Date:  2022-03-23       Impact factor: 5.486

4.  NAMPT Inhibitor and P73 Activator Represses P53 R175H Mutated HNSCC Cell Proliferation in a Synergistic Manner.

Authors:  Bi-He Cai; Zhi-Yu Bai; Ching-Feng Lien; Si-Jie Yu; Rui-Yu Lu; Ming-Han Wu; Wei-Chen Wu; Chia-Chi Chen; Yi-Chiang Hsu
Journal:  Biomolecules       Date:  2022-03-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.